Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil VSports app下载. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

Review
. 2016:2016:4273943.
doi: 10.1155/2016/4273943. Epub 2016 Dec 26.

The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches

Pankita H Pandya  1 , Mary E Murray  2 , Karen E Pollok  3 , Jamie L Renbarger  4
Affiliations
Review

The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches

Pankita H Pandya et al. J Immunol Res. 2016.

Abstract

Interplay among immune activation and cancer pathogenesis provides the framework for a novel subspecialty known as immunooncology. In the rapidly evolving field of immunooncology, understanding the tumor-specific immune response enhances understanding of cancer resistance. This review highlights the fundamentals of incorporating precision medicine to discover new immune biomarkers and predictive signatures VSports手机版. Using a personalized approach may have a significant, positive impact on the use of oncolytics to better guide safer and more effective therapies. .

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interests regarding the publication of this paper.

Figures

Figure 1
Figure 1
Overview of the immune system: innate and adaptive immunity. An evolutionary bridge between both forms of immunity is observed due to the presence of γδ T cells, NKT cells, NK cells, dendritic cells, macrophages, and complement proteins. The innate immune responses include cells and soluble components that are nonspecific, fast-acting, and first responders in inflammation. In contrast, adaptive immunity encompasses immune components that are more specific for targeted antigens and capable of forming immunological memory [25, 27, 38].
Figure 2
Figure 2
The cancer immunoediting process. There are three phases in the cancer immunoediting process: elimination, equilibrium, and escape [4]. Elimination phase involves effector function of the immune cells to target and eradicate cancer. In the equilibrium phase a balance is obtained between progression of cancer and cancer elimination by the immune system. If the cancer persists then it overwhelms the immunity and escapes to go on and metastasize to the other organs [4, 40, 53].
Figure 3
Figure 3
Immunotherapies in cancer. Several FDA approved immunotherapies have been approved in the market to prevent or control cancer progression [1]. On APCs (such as B cells), monoclonal antibodies targeting CD20 (Rituximab) results in downregulation of B cell activity [62]. Other antigen-presenting cells (macrophages and dendritic cells) are also activated by Imiquimod, a small molecule agonist for TLR7 [1]. For activation of T cells Keytruda (monoclonal antibody targeting PD-L1- PD-1 interaction) and Ipilimumab (antibody against CTLA4) are approved and in clinical use [1, 39]. Recombinant cytokines such as Proleukin (IL-2), Leukine (GM-CSF), and Filgrastim (G-CSF) are approved for stimulation/activation of T cells, myeloid cells, and neutrophils, respectively [1, 67].
See this image and copyright information in PMC

References

    1. Adams J. L., Smothers J., Srinivasan R., Hoos A. Big opportunities for small molecules in immuno-oncology. Nature Reviews Drug Discovery. 2015;14(9):603–621. doi: 10.1038/nrd4596. - DOI - PubMed
    1. Murphy K., Travers P., Walport M. Janeway's Immunobiology. 7th. New York, NY, USA: Garland Science Taylor and Francis Group; 2008. Principles of innate and adaptive immunity; pp. 1–38.
    1. Vesely M. D., Kershaw M. H., Schreiber R. D., Smyth M. J. Natural innate and adaptive immunity to cancer. Annual Review of Immunology. 2011;29:235–271. doi: 10.1146/annurev-immunol-031210-101324. - DOI - PubMed
    1. Schreiber R. D., Old L. J., Smyth M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565–1570. doi: 10.1126/science.1203486. - DOI - PubMed
    1. Hoos A., Britten C. M. The immuno-oncology framework enabling a new era of cancer therapy a new era of cancer therapy. OncoImmunology. 2012;1(3):334–339. doi: 10.4161/onci.19268. - "V体育ios版" DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources